An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer.

Trial Profile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs Golvatinib (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 12 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Actual patients number is 7 as reported by ClinicalTrials.gov.
    • 22 Feb 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-000774-58).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top